Illumina (ILMN) Stock Forecast & Price Target

Q: What analysts cover Illumina?

Illumina has been rated by research analysts at Barclays , Canaccord Genuity Group , Citigroup , Daiwa Securities Group , Deutsche Bank Aktiengesellschaft , Evercore , Guggenheim , JPMorgan Chase & Co. , Leerink Partners , Piper Sandler , Royal Bank Of Canada , Sanford C. Bernstein , Stifel Nicolaus , TD Cowen , Weiss Ratings , and Zacks Research in the past 90 days.

$187.96 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$186.67 -1.29 (-0.69%)

As of 07:34 AM Eastern

Compare

Illumina - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 17 Analyst Ratings

Sell
2

Hold
6

Buy
9

Based on 17 Wall Street analysts who have issued ratings for Illumina in the last 12 months, the stock has a consensus rating of "Hold." Out of the 17 analysts, 2 have given a sell rating, 6 have given a hold rating, 8 have given a buy rating, and 1 has given a strong buy rating for ILMN.

Consensus Price Target

$188.40
0.23% Upside

According to the 17 analysts' twelve-month price targets for Illumina, the average price target is $188.40. The highest price target for ILMN is $230.00, while the lowest price target for ILMN is $113.00. The average price target represents a forecasted upside of 0.23% from the current price of $187.96.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for ILMN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Illumina and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ILMN Analyst Ratings Over Time

Type	Current Forecast 8/10/25 to 8/10/26	1 Month Ago 7/11/25 to 7/11/26	3 Months Ago 5/12/25 to 5/12/26	1 Year Ago 8/10/24 to 8/10/25
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	8 Buy rating(s)	6 Buy rating(s)	8 Buy rating(s)
Hold	6 Hold rating(s)	9 Hold rating(s)	10 Hold rating(s)	8 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$188.40	$148.94	$131.06	$124.83
Forecasted Upside	0.23% Upside	-21.69% Downside	-10.05% Downside	32.01% Upside
Consensus Rating	Hold	Hold	Hold	Hold

ILMN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ILMN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Illumina Stock vs. The Competition

Type	Illumina	Healthcare Companies	Broader Market
Consensus Rating Score	2.47	2.30	2.53
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	0.23% Upside	862.08% Upside	11.64% Upside
News Sentiment Rating	Positive News See Recent ILMN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
8/5/2026	Deutsche Bank Aktiengesellschaft 2 of 5 stars		Downgrade	Hold
8/3/2026	Canaccord Genuity Group 4 of 5 stars	Kyle Mikson 3 of 5 stars	Boost Target	Hold	$190.00 ➝ $205.00	0.00%
8/3/2026	Citigroup 4 of 5 stars	Patrick Donnelly 4 of 5 stars	Boost Target	Sell	$95.00 ➝ $113.00	-44.90%
8/3/2026	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Strong-Buy
8/3/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Westenberg Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$200.00 ➝ $225.00	+11.29%
7/31/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Dan Leonard Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$170.00 ➝ $230.00	+15.48%
7/31/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Eve Burstein Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Market Perform	$215.00	+4.83%
7/31/2026	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Subbu Nambi Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$200.00 ➝ $226.00	+10.20%
7/31/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Luke Sergott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Underweight	$145.00 ➝ $160.00	-21.99%
7/31/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Casey Woodring Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$220.00 ➝ $230.00	+14.36%
Trump is positioned. Elon lights the fuse. (Ad) I hope you listened. Because here's what happened. The stock did exactly what these hyped mega-listings do. It rocketed out of the gate, ran all the way to about $225 a share, and sucked in every retail investor who couldn't stand to miss out. In three trading days, it shed nearly a quarter of its value and erased over $600 billion. It briefly fell below its very first trading price. The people who chased the top got exactly what Wall Street needed them to be: exit liquidity. But all that liquidity that just left the stock? It's not going into a bank account. Smart money is rotating it right into the next asset they believe will pop-off. Discover our #1 crypto for the SpaceX IPO rotation.
7/31/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Dan Brennan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Hold	$192.00 ➝ $210.00	+5.17%
7/31/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Daniel Arias Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$155.00 ➝ $225.00	+13.72%
7/17/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Puneet Souda Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$175.00 ➝ $210.00	+13.91%
7/6/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
6/3/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold (C-) ➝ Hold (C)
5/14/2026	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Neutral ➝ Outperform	$155.00	+6.90%
2/6/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Catherine Ramsey Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$137.00	+13.26%
2/6/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	John Sourbeer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Neutral	$135.00	+12.27%
8/4/2025	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target	Overweight	$110.00	+12.52%
8/4/2025	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tejas Savant Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$100.00 ➝ $105.00	+8.45%
7/11/2025	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sung Ji Nam Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Sector Outperform ➝ Sector Perform	$125.00	+24.94%
2/28/2025	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	S. Gupta Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$100.00	+18.76%
8/28/2024	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jasper Hellweg Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$150.00	+14.59%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 07:29 AM ET.

Should I Buy Illumina Stock? ILMN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, August 7, 2026. Please send any questions or comments about these Illumina pros and cons to contact@marketbeat.com.

Illumina
Bull Case

Here are some ways that investors could benefit from investing in Illumina, Inc.:

The current stock price is around $174, which is significantly lower than its fifty-two week high of $199.14, indicating potential for growth.
Illumina, Inc. reported a strong quarterly earnings performance, with earnings per share (EPS) of $1.15, surpassing analysts' expectations, which reflects robust financial health.
The company has a solid return on equity of 31.01%, suggesting effective management and profitability in generating returns for shareholders.
Illumina's revenue growth of 4.8% compared to the same quarter last year indicates a positive trend in sales and market demand for its products.
With a market cap of $29.48 billion, Illumina, Inc. is positioned as a significant player in the life sciences sector, which may attract institutional investors.

Illumina
Bear Case

Investors should be bearish about investing in Illumina, Inc. for these reasons:

The company has a relatively high price-to-earnings (P/E) ratio of 35.42, which may indicate that the stock is overvalued compared to its earnings.
Illumina's PEG ratio of 2.85 suggests that the stock's price may not be justified by its expected earnings growth, potentially leading to a correction.
The beta of 1.47 indicates that the stock is more volatile than the market, which could lead to higher risk for investors.
Despite recent revenue growth, the competitive landscape in the life sciences sector is intense, which could impact future performance.
The company's debt-to-equity ratio of 0.56, while manageable, indicates some reliance on debt financing, which could pose risks in a rising interest rate environment.

ILMN Forecast - Frequently Asked Questions

According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for Illumina is $188.40, with a high forecast of $230.00 and a low forecast of $113.00.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 2 sell ratings, 6 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ILMN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.

According to analysts, Illumina's stock has a predicted upside of 0.23% based on their 12-month stock forecasts.

Over the previous 90 days, Illumina's stock had 6 upgrades and 1 downgrade by analysts.

Illumina has been rated by research analysts at Barclays, Canaccord Genuity Group, Citigroup, Daiwa Securities Group, Deutsche Bank Aktiengesellschaft, Evercore, Guggenheim, JPMorgan Chase & Co., Leerink Partners, Piper Sandler, Royal Bank Of Canada, Sanford C. Bernstein, Stifel Nicolaus, TD Cowen, Weiss Ratings, and Zacks Research in the past 90 days.

Analysts like Illumina more than other "healthcare" companies. The consensus rating score for Illumina is 2.47 while the average consensus rating score for "healthcare" companies is 2.30. Learn more on how ILMN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Illumina Recommendations

This page (NASDAQ:ILMN) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Illumina (ILMN) Stock Forecast & Price Target